대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	Effect of GLP-1 & GLP-2 dual agonist (PG-102) on Tacrolimus-Induced Pancreatic and Renal Injury in a Rat Model
저자	Hyeran Park
출판정보	2026; 2026(1):
키워드	tacrolimus, diabetes mellitus, nephrotoxicity, GLP1 & 2 agonist
초록	Objectives: Tacrolimus (TAC) is widely used as an immunosuppressant but frequently causes metabolic disturbances, pancreatic β-cell dysfunction, and nephrotoxicity. We investigated the protective effects of GLP1 & 2 dual agonist (PG-102) against tacrolimus (TAC)-induced pancreatic and kidney injury. Methods: Sprague-Dawley rats were divided into 4 groups and treated with TAC (1.5 mg/kg/day, subcutaneously) with or without PG102 (30nmol/kg every other day) for five weeks. Metabolic parameters, HbA1c, urinary glucose excretion, creatinine clearance, oxidative stress, apoptosis markers, and histologic changes in the pancreas and kidneys were assessed. In vitro, human kidney-2 (HK-2) cells and insulin-secreting β -cell-derived (INS-1) cells cells were treated with TAC with or without PG102 to assess cell viability and reactive oxygen species (ROS) production. Results: TAC caused metabolic dysfunction, β-cell loss, and renal injury, whereas PG-102 co-treatment consistently mitigated these effects. PG-102 improved TAC-induced elevations in HbA1c, and urinary glucose excretion and preserved pancreatic islet area and markedly reduced renal interstitial fibrosis. In the kidney, PG-102 reversed TAC-mediated fibrotic and apoptotic signaling by restoring E-cadherin and Bcl-2 expression and suppressing α-SMA, TGF-β1, and Bax. In HK-2 and INS-1 cells, PG-102 improved TAC-induced loss of viability and suppressed ROS production in a dose-dependent manner. Conclusion: Targeting both GLP1 & 2 may provide a potent therapeutic strategy for managing TAC-induced pancreatic and kidney injury.
원문(PDF)	PDF 원문보기

목록

위로가기